This publication aims to support the strengthening of antenatal screening programmes for HIV, hepatitis B, syphilis and rubella susceptibility in the general population and in groups identified as vulnerable to mother-to-child-transmission in the EU/EEA.
This document provides guidance for developing innovative and effective communication strategies to promote a culture of lower risk behaviour in the MSM community in the European Union and European Economic Area.
The aim of this document is to highlight measures that can effectively reduce the risk of importation and local transmission of pathogens transmitted by Ae. aegypti and Ae. albopictus. The main diseases of concern in this context are Zika, dengue, chikungunya and yellow fever.
This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.
The number of new HIV cases diagnosed annually in Cyprus has been on the rise since 2005: more than 50 new cases of HIV were diagnosed every year from 2011 to 2013. This report addresses this issue and provides options on how Cyprus can respond to the epidemic.
At the request of the Ministry of Health in Riga, a team of experts from ECDC and the European Monitoring Centre for Drugs and Drug Addiction paid a technical visit to Latvia on 2–4 September 2014.
Despite efforts to prevent new HIV infections, more than 27 000 people were newly diagnosed with HIV in the European Union (EU) and the European Economic Area (EEA) in 2010.
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.